Keros Therapeutics Newsroom

Keros Therapeutics Is Maintained at Sector Outperform by Scotiabank

Dow Jones03:56

Jefferies Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23

Futu NewsDec 13 23:32

Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating

Futu NewsDec 13 21:32

Scotiabank Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $44

Futu NewsDec 13 21:31

A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $47 to $84

Futu NewsDec 13 21:00

HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Lowers Price Target to $47

BenzingaDec 13 19:36

Keros Therapeutics Cut to Market Perform From Outperform by William Blair

Dow JonesDec 13 03:22

Keros Therapeutics Analyst Ratings

BenzingaDec 13 01:50

Wedbush Adjusts Price Target on Keros Therapeutics to $47 From $84, Keeps Outperform Rating

MT NewswiresDec 12 23:59

Keros Therapeutics Is Maintained at Overweight by Wells Fargo

Dow JonesDec 11 23:35

Keros Therapeutics Analyst Ratings

BenzingaDec 11 23:24

Wells Fargo Maintains Keros Therapeutics(KROS.US) With Buy Rating, Raises Target Price to $111

Futu NewsDec 11 20:31

Wells Fargo Sticks to Its Buy Rating for Keros Therapeutics (KROS)

TipRanksDec 11 20:02

Wedbush Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $84

Futu NewsDec 11 00:31

Piper Sandler Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $105

Futu NewsDec 9 20:33

Oppenheimer Keeps Their Buy Rating on Keros Therapeutics (KROS)

TipRanksDec 6 00:56

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Incyte (INCY) and Prenetics Group (PRE)

TipRanksDec 6 00:04

Strategic Partnership and Financial Strength Bolster Keros Therapeutics' Buy Rating

TipRanksDec 5 23:32

Keros Therapeutics Analyst Ratings

BenzingaDec 4 21:59

Wedbush Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $84

Futu NewsNov 25 23:31